Johnson & Johnson May Be Forced To License Stents Patents To Complete Major Acquisition

Law360, New York (August 29, 2005, 12:00 AM EDT) -- The European Commission ruled this week Johnson & Johnson may need to license Guidant Corp.’s patents, which are held up in litigation, before acquisition of Guidant will be granted final approval.

The $25 billion dollar cash and stock deal would be the largest ever in the medical device industry and biggest in the 118-year history of Johnson & Johnson, maker of drugs, baby products, orthopedic and other health products.

Johnson & Johnson and Guidant are active worldwide in vascular medical devices, with their products used to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.